Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients.
Adult
Aged
Aged, 80 and over
CD8-Positive T-Lymphocytes
/ immunology
Carcinoma, Squamous Cell
/ immunology
Humans
Lymph Nodes
/ immunology
Lymphatic Metastasis
/ immunology
Lymphocytes, Tumor-Infiltrating
/ drug effects
Male
Middle Aged
Neoadjuvant Therapy
Papillomavirus Infections
/ immunology
Penile Neoplasms
/ immunology
Adoptive cellular immunotherapy
Immunophenotyping
Penile cancer
T cells
Tumor-infiltrating lymphocytes
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
08
12
2020
revised:
02
02
2021
accepted:
04
02
2021
pubmed:
27
2
2021
medline:
10
6
2021
entrez:
26
2
2021
Statut:
ppublish
Résumé
Penile cancer is a rare but highly lethal cancer, and therapeutic options for patients presenting with lymph nodal disease are very limited. Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) was shown to provide durable objective response in patients with metastatic melanoma and TIL have been expanded from solid tumors at rates between 70 and 90% depending on the specific diagnosis. We evaluated whether TIL could be expanded from surgical specimens of patients with penile cancer. Tumor samples from metastatic lymph nodes obtained at the time of inguinal lymph node dissection were collected, minced into fragments, placed in individual wells of a 24-well plate, and propagated in high dose IL-2 for four weeks. The phenotype of expanded TILs was assessed by flow cytometry and their anti-tumor reactivity was assessed by IFN-γ ELISA. TIL were expanded from 11 out of 12 (91.6%) samples of metastatic lymph nodes. Expanded TIL were predominantly CD3
Identifiants
pubmed: 33636562
pii: S1567-5769(21)00117-X
doi: 10.1016/j.intimp.2021.107481
pmc: PMC8205103
mid: NIHMS1674093
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
107481Subventions
Organisme : NCI NIH HHS
ID : R01 CA241559
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA239219
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA252642
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA244100
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA193489
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA076292
Pays : United States
Organisme : NCI NIH HHS
ID : F31 CA250320
Pays : United States
Organisme : NCI NIH HHS
ID : K23 CA178083
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Science. 2017 Apr 14;356(6334):200-205
pubmed: 28408606
Urol Oncol. 2013 Jul;31(5):505-16
pubmed: 21481617
Therap Adv Gastroenterol. 2020 Aug 21;13:1756284820948773
pubmed: 32913444
Clin Cancer Res. 2010 Dec 15;16(24):6122-31
pubmed: 20668005
Transl Androl Urol. 2017 Oct;6(5):820-825
pubmed: 29184778
J Urol. 2011 Mar;185(3):888-93
pubmed: 21239009
J Urol. 2019 Mar;201(3):541-548
pubmed: 30291913
Expert Opin Biol Ther. 2017 Nov;17(11):1417-1431
pubmed: 28832261
Clin Cancer Res. 1995 May;1(5):501-7
pubmed: 9816009
Urology. 2010 Aug;76(2 Suppl 1):S66-73
pubmed: 20691887
Tumour Biol. 2015 Apr;36(4):2509-16
pubmed: 25557886
Front Immunol. 2018 Jun 11;9:1253
pubmed: 29942303
J Immunother. 2012 Jun;35(5):400-8
pubmed: 22576345
Lancet Oncol. 2019 Jan;20(1):145-158
pubmed: 30573285
JAMA Oncol. 2018 May 1;4(5):643-649
pubmed: 29494739
PLoS One. 2013;8(4):e60031
pubmed: 23560068
Nat Rev Urol. 2020 Oct;17(10):555-570
pubmed: 32812000
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Immunother. 2003 Jul-Aug;26(4):332-42
pubmed: 12843795
J Natl Compr Canc Netw. 2013 May 1;11(5):594-615
pubmed: 23667209
BJU Int. 2006 Sep;98(3):526-31
pubmed: 16925747
Eur Urol Focus. 2019 Sep;5(5):706-709
pubmed: 31160252
J Surg Oncol. 2006 Feb 1;93(2):133-8
pubmed: 16425300
Clin Cancer Res. 2011 Jul 1;17(13):4550-7
pubmed: 21498393
J Urol. 2020 Jun;203(6):1147-1155
pubmed: 31928407
J Immunother. 2012 Oct;35(8):615-20
pubmed: 22996367
J Urol. 2010 Oct;184(4):1347-53
pubmed: 20723934
Cancers (Basel). 2020 Sep 21;12(9):
pubmed: 32967162
J Clin Oncol. 2015 May 10;33(14):1543-50
pubmed: 25823737
PLoS One. 2011 Mar 02;6(3):e17517
pubmed: 21407808